Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150
Nephron Research Adjusts Price Target on DexCom to $125 From $145
DexCom Is Maintained at Buy by Citigroup
DexCom Is Maintained at Overweight by Wells Fargo
DexCom Analyst Ratings
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $94
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Announces Target Price $90
DexCom Is Maintained at Buy by Canaccord Genuity
DexCom Analyst Ratings
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $99
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Sticks to Its Buy Rating for Dexcom (DXCM)
Wells Fargo Remains a Buy on Dexcom (DXCM)
J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $85 to $115